Lupin Launches Generic Motegrity for CIC Treatment

  Published 11 months ago

Lupin’s generic Prucalopride treats CIC in adults bioequivalent to Motegrity, made in Goa, India. IQVIA data shows $184M annual US sales for Prucalopride (Motegrity reference drug) in April 2025. Lupin, a Mumbai based global leader, distributes products in 100+ markets, specializing in diverse pharmaceuticals.

  • Lupin’s generic Prucalopride treats CIC in adults bioequivalent to Motegrity, made in Goa, India.
  • IQVIA data shows $184M annual US sales for Prucalopride (Motegrity reference drug) in April 2025.
  • Lupin, a Mumbai, based global leader, distributes products in 100+ markets, specializing in diverse pharmaceuticals.

You might like these

Wipro & Entrust: Accelerating Secure Identity Solutions

REC Results: Income Surge & Dividend

India Seeks FATF Grey List for Pakistan

Trump Slams India-Russia Ties, Hikes Tariffs

India’s Electronics Export Boom

Sun Pharma Q4 FY25: Strong Growth & Dividends

Safran and PTC Expand India Aerospace Collaboration

News that matters the most ⚡